JP2019523284A - 子宮内膜症の治療および/または防止用薬剤 - Google Patents
子宮内膜症の治療および/または防止用薬剤 Download PDFInfo
- Publication number
- JP2019523284A JP2019523284A JP2019505211A JP2019505211A JP2019523284A JP 2019523284 A JP2019523284 A JP 2019523284A JP 2019505211 A JP2019505211 A JP 2019505211A JP 2019505211 A JP2019505211 A JP 2019505211A JP 2019523284 A JP2019523284 A JP 2019523284A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- parsley
- endometriosis
- drops
- oleander
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 94
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 229940079593 drug Drugs 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title claims abstract description 48
- 230000002265 prevention Effects 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 77
- 229940117336 parsley extract Drugs 0.000 claims abstract description 56
- 241000893864 Nerium Species 0.000 claims description 52
- 238000010790 dilution Methods 0.000 claims description 22
- 239000012895 dilution Substances 0.000 claims description 22
- 229940098465 tincture Drugs 0.000 claims description 21
- 241000208317 Petroselinum Species 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 7
- 208000007190 Chlamydia Infections Diseases 0.000 claims description 5
- 230000000843 anti-fungal effect Effects 0.000 claims description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 230000002725 anti-mycoplasma Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 230000028709 inflammatory response Effects 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 1
- 244000187664 Nerium oleander Species 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 41
- 230000036407 pain Effects 0.000 description 41
- 239000006196 drop Substances 0.000 description 30
- 230000002357 endometrial effect Effects 0.000 description 29
- 238000002560 therapeutic procedure Methods 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 18
- 208000000509 infertility Diseases 0.000 description 16
- 230000036512 infertility Effects 0.000 description 16
- 231100000535 infertility Toxicity 0.000 description 16
- 230000003902 lesion Effects 0.000 description 15
- 230000002354 daily effect Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000000450 Pelvic Pain Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 235000011197 perejil Nutrition 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 8
- 230000002611 ovarian Effects 0.000 description 8
- 230000027758 ovulation cycle Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000035558 fertility Effects 0.000 description 7
- 238000001794 hormone therapy Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229960000766 danazol Drugs 0.000 description 6
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 239000003539 oral contraceptive agent Substances 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000001784 detoxification Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000002357 laparoscopic surgery Methods 0.000 description 5
- 229940127234 oral contraceptive Drugs 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 206010058841 Adnexa uteri pain Diseases 0.000 description 3
- 241000271532 Crotalus Species 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010065951 Retrograde menstruation Diseases 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000003511 ectopic pregnancy Diseases 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 239000002474 gonadorelin antagonist Substances 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- CKAPSXZOOQJIBF-UHFFFAOYSA-N hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003993 organochlorine pesticide Substances 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000208306 Apium Species 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010049872 Breast discomfort Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010061178 Genital haemorrhage Diseases 0.000 description 1
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 235000002770 Petroselinum crispum Nutrition 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 238000011538 abdominal hysterectomy Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000185 dioxinlike effect Effects 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960004761 gestrinone Drugs 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 101150108262 gnrh1 gene Proteins 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- OCHOKXCPKDPNQU-FLVMBEMLSA-N trans-Nonachlor Chemical compound ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H](Cl)C(Cl)[C@@H](Cl)[C@@H]3[C@@]1(Cl)C2(Cl)Cl OCHOKXCPKDPNQU-FLVMBEMLSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
経口避妊薬を使用すると、痛みの減少は一時的であり、月経周期が止められているときである避妊薬自体を服用している間のみ有効である。子宮内膜症の症状は治療の中断とともに再発する。
プロゲステロンとプロゲスチンとは、錠剤として、長期にわたる注射で、または子宮内避妊器具ミレーナ(MirenaR intrauterine device)(登録商標)として服用され、子宮内膜病変部の大きさを縮小することによって症状を改善し、また、月経を減少するか、または完全に妨げる(プロゲステロン子宮内螺旋状避妊具を使用する女性の3分の1は、1年間の治療後、もはや月経を有しない。)
このホルモンは身体を「閉経期」状態に置くことによって、卵巣性ホルモンの産生を妨げる点においてさらに強力である。それは(上述した療法のように)ホルモン補充無しに排卵、月経、子宮内膜の成長を止め、したがって子宮内膜症の成長を止め、また、連続して6ヵ月を超えて服用することはできない。
ダナゾールは月経周期のホルモン産生を妨げる。ダナゾールを用いた治療の間、女性は非常に不規則な月経を有し、また時に、それを全く有しない。非常に一般的な副作用は、にきびおよび体重の増加、筋肉の痙攣、倦怠感、乳房の張りおよび縮小、頭痛、めまい、脱力感、紅潮、男性調の発声である。
・クラミジア感染症、マイコプラズマ感染症およびウイルス感染症等の感染症。
・そのすべてが子宮内膜症細胞を反応させる、髪の上で使用される化学物質(これに対しては美容師は専ら曝されている)や、接着剤や溶媒等からの中毒。
以前に左の卵管切除を行って子宮外妊娠をした25歳の患者が検査された。彼女は月経疼痛のためにラパロスコピーも受けており、妊娠を望んでおり、広範囲の子宮内膜癒着と子宮内膜の病巣との診断を受けていた。ラパロスコピーの後、ひどい生理痛に変化が無いことを訴えており、また、子供を欲しがっていたができなかったので、不妊症カウンセリングを求めていた。
11年前に子宮外妊娠をした31歳の患者が検査された。彼女はその2年前に子宮内膜症のために腹腔鏡下手術も受けており、それが子宮内膜症疾患と右の卵管の閉塞とを確認していた。多くの癒着が存在していた。患者は月経中の重度の痛みを訴えていた。
3cmの子宮内膜嚢胞を有し、また、子宮内膜症関連の痛みのため約2年間継続的な経口避妊薬療法を受けていた33歳の患者が、検査された。子供が欲しかったため、彼女は最近、療法を中断した。
子宮内膜症の診断を受けていて、非常に重度の骨盤痛、月経痛、直腸痛、性交疼痛および不妊症を訴えていた、41歳の患者が往診された。
Claims (21)
- 子宮内膜症の治療および/または防止において使用するパセリ抽出物を備える薬剤。
- 前記パセリ抽出物は、ペトロセリウムクリスプム抽出物と、ペトロセリウムサティバム抽出物と、ペトロセリウムセゲトゥム抽出物とから成る群から選択された抽出物であり、より好ましくは、ペトロセリウムクリスプム抽出物である、請求項1に記載の薬剤。
- 前記パセリ抽出物は前記パセリ植物全体の抽出物であり、好ましくは、新鮮な前記パセリ植物の抽出物である、請求項1または2に記載の薬剤。
- 前記パセリ抽出物は溶液、タブレット、カプセル、および粉から選択された形状であり、好ましくは溶液の形状である、請求項1〜3のいずれか一項に記載の薬剤。
- 経口投与用の、請求項1〜4のいずれか一項に記載の薬剤。
- 20日〜90日間の、好ましくは30日〜70日間の投与期間投与される、請求項1〜5のいずれか一項に記載の薬剤。
- 前記投与期間の後に、20日〜90日間の、好ましくは30日〜70日間の前記薬剤のさらなる投与期間が続く、請求項6に記載の薬剤。
- 前記薬剤はマザーチンクチャーの形状で前記パセリ抽出物を備え、また、前記薬剤は20日〜90日間の、好ましくは30日〜70日間の投与期間、1日につき前記パセリ抽出物の10滴〜30滴、好ましくは1日につき前記パセリ抽出物の10滴〜20滴の投与量で投与される、請求項3〜7のいずれか一項に記載の薬剤。
- 20日〜90日間の、好ましくは30日〜70日間の投与期間、1日2回、前記パセリ抽出物の5滴〜15滴、好ましくは1日2回、前記パセリ抽出物の5滴〜10滴の投与量で投与される、請求項8に記載の薬剤。
- オレアンダー抽出物をさらに備える、請求項1〜9のいずれか一項に記載の薬剤。
- 前記オレアンダー抽出物は、ネリウムオレアンダー抽出物とネリウムインディカム抽出物とから成る群から選択され、好ましくはネリウムオレアンダー抽出物である、請求項10に記載の薬剤。
- 前記オレアンダー抽出物はオレアンダーの抽出物である、請求項10または11に記載の薬剤。
- 前記オレアンダー抽出物は溶液、タブレット、カプセル、および丸薬から選択された形状であり、好ましくは溶液の形状である、請求項10〜12のいずれか一項に記載の薬剤。
- 前記オレアンダー抽出物は前記溶液の形状であって、溶媒中での抽出と、そのようにして得られた中間抽出物の溶媒中でのさらなる希釈とから得られ、4DH〜60DHの、好ましくは4DH〜6DHの10倍希釈物を得る(ハーネマン希釈)、請求項13に記載の薬剤。
- 前記薬剤は経口投与用の医薬形態であり、子宮内膜症の治療、および/または防止用の、同時の、別々の、または逐次的な使用のため、前記パセリ抽出物を、好ましくはマザーチンクチャーの形状で備え、また前記オレアンダー抽出物を、好ましくは4DH〜6DHの10倍希釈で備える、請求項10〜14のいずれか一項に記載の薬剤。
- 前記薬剤は、前記パセリ抽出物と前記オレアンダー抽出物とを6:1〜1:1の、好ましくは3:1〜2:1の、より好ましくは2:1のウェイトレシオで、前記パセリ抽出物を、好ましくはマザーチンクチャーの形状で、また前記オレアンダー抽出物を、好ましくは4DH〜6DHの10倍希釈で備える、請求項10〜15のいずれか一項に記載の薬剤。
- 前記薬剤は前記パセリ抽出物をマザーチンクチャーの形状で、また前記オレアンダー抽出物を4〜6DHの10倍希釈物の形状で備え、また、前記薬剤は20日〜90日間の、好ましくは30日〜70日間の投与期間、1日につき1回、前記パセリ抽出物の10滴〜30滴、好ましくは1日につき1回、前記パセリ抽出物の10滴〜20滴の投与量で、また、1日につき1回、前記オレアンダー抽出物の5滴〜10滴、好ましくは1日につき1回、前記オレアンダー抽出物の5滴または6滴の投与量で投与される、請求項10〜16のいずれか一項に記載の薬剤。
- 20日〜90日間の、好ましくは30日〜70日間の投与期間、1日2回、前記パセリ抽出物の5滴〜15滴、好ましくは1日2回、前記パセリ抽出物の5滴〜10滴の投与量で、また、1日2回、前記オレアンダー抽出物の3滴〜5滴、好ましくは1日2回、前記オレアンダー抽出物の2滴または3滴の投与量で投与される、請求項17に記載の薬剤。
- 前記子宮内膜症細胞の前記炎症反応の前記引き金となる原因を取り除くため、子宮内膜症の診断に続けて、抗炎症薬品、肝臓および/または腎臓および/または腸の排液薬品、抗生物質薬品、抗マイコプラズマ薬品、抗クラミジア感染症薬品、抗真菌薬品、および抗ウイルス薬品の中の1つ以上の薬品を用いた1つ以上の前治療を以前に受けた患者に投与される、請求項1〜18のいずれか一項に記載の薬剤。
- 前記子宮内膜症の治療、および/または前記防止用の、(a)前記パセリ抽出物と、(b)前記オレアンダー抽出物とを備える部品のキット。
- 請求項1〜19のいずれか一項に記載の前記薬剤または請求項20に記載の前記キットを、それを必要とする患者へ投与することを備える子宮内膜症の治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000080802 | 2016-08-01 | ||
IT102016000080802A IT201600080802A1 (it) | 2016-08-01 | 2016-08-01 | Medicamento per il trattamento e/o la prevenzione dell’endometriosi. |
PCT/IB2017/054667 WO2018025165A1 (en) | 2016-08-01 | 2017-07-31 | Medicament for the treatment and/or prevention of endometriosis |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019523284A true JP2019523284A (ja) | 2019-08-22 |
JP2019523284A5 JP2019523284A5 (ja) | 2020-08-27 |
JP7229911B2 JP7229911B2 (ja) | 2023-02-28 |
Family
ID=57851147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019505211A Active JP7229911B2 (ja) | 2016-08-01 | 2017-07-31 | 子宮内膜症の治療および/または防止用薬剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10702566B2 (ja) |
EP (1) | EP3490604B1 (ja) |
JP (1) | JP7229911B2 (ja) |
AU (1) | AU2017305682B2 (ja) |
BR (1) | BR112019001932A2 (ja) |
CA (1) | CA3032112A1 (ja) |
HR (1) | HRP20240244T1 (ja) |
IT (1) | IT201600080802A1 (ja) |
MX (1) | MX2019001335A (ja) |
PL (1) | PL3490604T3 (ja) |
RS (1) | RS65225B1 (ja) |
RU (1) | RU2759836C2 (ja) |
WO (1) | WO2018025165A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2020130847A (ru) * | 2018-04-02 | 2022-05-04 | Нериум Биотекнолоджи, Инк. | РАСТИТЕЛЬНЫЕ ЭКСТРАКТЫ Nerium oleander И СПОСОБЫ ЭКСТРАКЦИИ |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060135443A1 (en) * | 2004-10-18 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Use of Na*/K*-ATPase inhibitors and antagonists thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7402325B2 (en) * | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
WO2010036973A1 (en) * | 2008-09-25 | 2010-04-01 | Comgenrx, Inc. | Treatment of hyperproliferative disorders using cardiac glycosides |
CN103432530B (zh) * | 2013-09-06 | 2014-12-17 | 云南盘龙云海药业有限公司 | 一种治疗子宫内膜异位症的中药组合物及其制备方法 |
KR20150095329A (ko) * | 2014-02-13 | 2015-08-21 | 송상민 | 천연 살충제의 제조방법 |
-
2016
- 2016-08-01 IT IT102016000080802A patent/IT201600080802A1/it unknown
-
2017
- 2017-07-31 RU RU2019103294A patent/RU2759836C2/ru active
- 2017-07-31 US US16/321,980 patent/US10702566B2/en active Active
- 2017-07-31 BR BR112019001932A patent/BR112019001932A2/pt not_active Application Discontinuation
- 2017-07-31 RS RS20240226A patent/RS65225B1/sr unknown
- 2017-07-31 EP EP17761330.4A patent/EP3490604B1/en active Active
- 2017-07-31 PL PL17761330.4T patent/PL3490604T3/pl unknown
- 2017-07-31 CA CA3032112A patent/CA3032112A1/en active Pending
- 2017-07-31 JP JP2019505211A patent/JP7229911B2/ja active Active
- 2017-07-31 WO PCT/IB2017/054667 patent/WO2018025165A1/en active Application Filing
- 2017-07-31 AU AU2017305682A patent/AU2017305682B2/en active Active
- 2017-07-31 HR HRP20240244TT patent/HRP20240244T1/hr unknown
- 2017-07-31 MX MX2019001335A patent/MX2019001335A/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060135443A1 (en) * | 2004-10-18 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Use of Na*/K*-ATPase inhibitors and antagonists thereof |
Non-Patent Citations (6)
Title |
---|
ANONYMOUS: "NATURLICHE HEILMITTEL FUR ENDOMETRIOSE", UBLICH ISOLIERT, JPN5019006941, February 2013 (2013-02-01), pages 1 - 4, ISSN: 0004897872 * |
BRITISH JOURNAL OF NUTRITION, 1999, VOL.81, P.447-455, JPN6021023825, ISSN: 0004897875 * |
FERTILITY & STERILITY, 2009, P.S11(O-35), JPN6021023826, ISSN: 0004897874 * |
MARYAM REZAZAD; ET AL: "PROTECTIVE EFFECT OF PETROSELINUM CRISPUM EXTRACT IN ABORTION USING PROSTADIN-INDUCED", AVICENNA JOURNAL OF PHYTOMEDICINE, vol. VOL:4, NR:5, JPN5019006942, September 2014 (2014-09-01), IR, pages 312 - 319, XP055365784, ISSN: 0004897870 * |
OSOSKI ANDREANA L; ET AL: "ETHNOBOTANICAL LITERATURE SURVEY OF MEDICINAL PLANTS IN THE DOMINICAN REPUBLIC USED", JOURNAL OF ETHNOPHARMACOLOGY, vol. VOL:79, NR:3, JPN5019006943, March 2002 (2002-03-01), IE, pages 285 - 298, ISSN: 0004897871 * |
STEROIDS, 2012, VOL.77 NO.7, P.765-773., JPN6021023827, ISSN: 0004897873 * |
Also Published As
Publication number | Publication date |
---|---|
AU2017305682A1 (en) | 2019-02-21 |
AU2017305682B2 (en) | 2022-12-15 |
CA3032112A1 (en) | 2018-02-08 |
RU2759836C2 (ru) | 2021-11-18 |
US20190167741A1 (en) | 2019-06-06 |
EP3490604A1 (en) | 2019-06-05 |
EP3490604C0 (en) | 2023-11-29 |
RS65225B1 (sr) | 2024-03-29 |
BR112019001932A2 (pt) | 2019-05-07 |
MX2019001335A (es) | 2019-04-25 |
IT201600080802A1 (it) | 2018-02-01 |
RU2019103294A (ru) | 2020-09-01 |
WO2018025165A1 (en) | 2018-02-08 |
JP7229911B2 (ja) | 2023-02-28 |
HRP20240244T1 (hr) | 2024-05-10 |
EP3490604B1 (en) | 2023-11-29 |
PL3490604T3 (pl) | 2024-04-29 |
RU2019103294A3 (ja) | 2020-12-02 |
US10702566B2 (en) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA028780B1 (ru) | Применение эстетрола в качестве экстренного контрацептива | |
RU2697051C2 (ru) | Комбинированный лекарственный препарат для профилактики инфекций, передающихся половым путём | |
PL212010B1 (pl) | Zastosowanie diacereiny lub jej farmaceutycznie dopuszczalnej pochodnej | |
TWI785178B (zh) | 片仔癀及其製劑在治療帶狀皰疹中的用途 | |
JPH04273822A (ja) | 子宮内膜症の治療薬 | |
JP7229911B2 (ja) | 子宮内膜症の治療および/または防止用薬剤 | |
EP3222283B1 (en) | Lentinan for use in the treatment of endometriosis | |
Sokal et al. | Transcervical quinacrine sterilization: clinical experience | |
AU2010263478A1 (en) | Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids | |
CN102552665B (zh) | 一种用于治疗妇科疾病的外用中药组合物 | |
JP2023528884A (ja) | 疾患の処置用の2-(ジエチルアミノ)エチル2-(4-イソブチルフェニル)プロピオネートの局所投与 | |
CN111437300A (zh) | 一种清热燥湿、散风止痒的中药组合物及其制备方法 | |
Levitsky et al. | Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case | |
Heaton | Antimalarials in treatment of Sjögren's syndrome | |
CN103599228B (zh) | 一种用于防治痔疮形成的中药 | |
Yuzpe | Postcoital contraception | |
Naram et al. | Ayurveda Interventions in the Management of Tubal Blockages-Case Studies | |
CN107929338A (zh) | 片仔癀及其制剂在制备治疗带状疱疹后遗神经痛的药物中的新用途 | |
US20140011837A1 (en) | Compositions and methods for treating warts associated with viral infections | |
UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
Sangy et al. | Potassium alum vaginal suppository: irritation assessment in rabbit | |
Dobrokhotova et al. | Primary dysmenorrhea: strategy and tactics of treatment | |
EP1109549B1 (en) | Analgesic use of podophyllotoxin for treating pain conditions in female genital organs | |
CN114984167A (zh) | 用于异位妊娠的中药组合物、异位妊娠合剂及其制备方法和应用 | |
CN113521169A (zh) | 一种用于治疗妇科炎症的药物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200714 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200714 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220909 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220912 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220930 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230215 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7229911 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |